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Reactive oxygen speciesa b s t r a c t
Although Oncolytic viruses have been regarded as a promising tool for targeted therapy of cancer, accom-
plishing high efficacy and specificity with this strategy is challenging. Oncolytic virotherapy is one of the
novel therapeutic methods recently used for the therapy of human malignancies. Cervical cancer is on the
major public health problem and the second most common cause of cancer death among females in less
developed countries. The aim of this study was mainly to determine the apoptosis effect of oncolytic
Newcastle disease virus (NDV) in TC-1 cell line.
In the current study, the oncolytic NDV, vaccine strain LaSota, was used to infect murine TC-1 cells of
human papillomavirus (HPV)-associated carcinoma which expressing human papillomavirus 16 (HPV-
16) E6/E7 antigens in vitro. The effectiveness of NDV for cervical cancer cell line was investigated by eval-
uating the antitumor activity of oncolytic NDV and the involved mechanisms. Antitumor activities of
oncolytic NDV were assessed by cell proliferation (MTT) and lactate dehydrogenase (LDH) release anal-
ysis. In addition, molecular changes of early stage of apoptosis and the role of reactive oxygen species
(ROS) were analyzed by flow cytometry and Western Blot in NDV-treated TC-1 cells.
The results showed that NDV treatment significantly decreased the viability of a TC-1 cell line and sup-
pressed the growth by inducing apoptotic cell death. In addition, we demonstrated that NDV-induced
apoptosis of TC-1 cells is mediated by ROS production. In summary, our findings suggest that oncolytic
NDV is a possible therapeutic candidate as a selective antitumor agent for the treatment of cervical
cancer.
 2019 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cervical cancer is known as of the most frequent malignancies
which can be observed among women all around the globe, with
annual 530,000 new cases and 250,000 deaths (Liu et al., 2018,
Gableh et al., 2016, Mohebbi et al., 2019). Unusual vaginal bleeding
is one of the most common symptom of cervical malignancy inadvance stage. The major causes of this cancer include Human
papillomaviruse-16 (HPV-16) and HPV-18, being responsible for
nearly 70% of all cervical cancers (Khan et al., 2005, Descamps
et al., 2009). Viral early proteins E6/E7 play a key role in the pro-
gression of this cancer (Park et al., 2016, Baghban Rahimi et al.,
2018). Surgery, radiotherapy, chemotherapy, immunotherapy or
combination of these methods are common treatments for cervical
cancer. Since these currently developed treatments have shown
several drawbacks, novel approaches are highly required to effi-
ciently address the therapeutic challenges. Among the possible
alternative strategies, oncolytic viruses have been regarded as
promising therapeutic candidates for cancer therapy (Zamarin
et al., 2014).
One of the characteristics which distinguish the cancer cells
from the normal cells is deficiency in Interferon (IFN) pathway.
By making the most of this defect, oncolytic viruses can continues
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induction of oncolysis (Yurchenko et al., 2018). Oncolytic viruses
(OVs) are a class of viruses that selectively replicate in malignant
cells and subsequently diffuse in a tumor without damaging the
normal cells. So far, two oncolytic viruses Onyx-015 (in China)
and T-VEC (in USA) were approved for head and neck squamous
cell carcinoma (HNSCC) and metastatic melanoma subjects,
respectively (Russell and Peng, 2018, Woller et al., 2014). These
viruses are classified into two groups: (i) those naturally replicat-
ing and damaging the cancer cells with no pathogenicity in
humans, and (ii) genetically engineered viruses that are used as
vaccine vectors (Jhawar et al., 2017).
Newcastle disease virus (NDV) is a member of naturally oncoly-
tic viruses which belongs to the genus Avulavirus, family Paramyx-
oviridae and causes severe illness in birds and poultry. Therefore,
since this virus is non-pathogenic in mammals, it can be used as
an agent for cancer treatment (Schwaiger et al., 2017). NDV catego-
rized into three pathotypes according to chicken pathogenicity,
including lentogenic (avirulent), mesogenic (intermediate), and
velogenic (virulent). LaSota and Hitchner B1 are lentogenic strains
that to be considered as live vaccines against Newcastle disease
(Panda et al., 2004). NDV has completed phase I/II clinical trial in
patients with glioma, and preclinical studies have been mainly
focused on the direct effect of this virus in vivo. A study has
demonstrated the effect of NDV on different cancer models such
as glioma and melanoma (Koks et al., 2015). However, there is a
paucity of information regarding the role of this virus in cervical
cancer. For this purpose, we evaluated the oncolytic potential of
NDV (Lasota) on TC-1 cells, which is cervical cancer model of C57
mice.2. Materials and methods
2.1. Cell culture
Mouse TC-1 cells (express HPV-16 E6/7 oncoproteins and pur-
chased from the cell bank of Pasteur Institute, Tehran, Iran) were
grown in complete DMEM medium (Gibco, UK) containing 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 25 mM HEPES, peni-
cillin (100 U/ml) and streptomycin (100 lg/ml) at 37 C with 5%
CO2.
2.2. NDV purification
The LaSota strain of NDV vaccine was prepared and inoculated
into allantoic cavity of embryonated specific pathogens free (SPF)
eggs, purchased from Razi Vaccine and Serum Research Institute
(Tehran, Iran). After 120 h, the allantoic fluid was collected, fol-
lowed by centrifuging at 4 C. In the next step, the supernatant
was separated and centrifuged for 3 h at 4 C (30,000 g/min). The
re-suspension of purified virus was carried out in Phosphate-
buffered saline (PBS) (pH 7.4), followed by titration via haemagglu-
tination (HA) test. Eventually, obtained virus was stored at 80 C
for further analysis.
2.3. MTT assay
The cytotoxic effects of the NDV was evaluated by Cell Prolifer-
ation assay Kit (MTT) (sigma, USA). For this regards, TC-1 cells were
seeded in each well of plates at a 3.0  104 density and were grown
in these cell culture plates for 24 h. After infecting the cells with
NDV at Multiplicity of infections (MOIs) of 1, 5, 10, 20 and 40 for
1 h, mediumwas removed and renewed by DMEM. Following incu-
bation time of 72 h, each well received 100 ll of MTT solution with
subsequent incubation at 37 C for 3 h. After removing incubationmedium, 100 ll dimethyl sulfoxide (DMSO) was used to dissolve
the purple crystals of formazan. Finally, the absorbance was mea-
sured at 540 nm using absorbance microplate reader aiming to
assess the MTT reduction (Anthos Labtec Instruments, Austria).
Each test was repeated at least three times.2.4. LDH release measurement
Cell lysis was determined by evaluation the secretion of lactate
dehydrogenase (LDH) into culture medium by LDH assay kit
(Takara Bio, Tokyo, Japan), with following the protocol of the kit.
Briefly speaking, TC-1 cells were placed at a 3.0  104 cells/100 ll
density in 96-well plates, and were infected with NDV at MOIs of 1,
5, 10, 20 and 40 for 1 h. after that the media (DMEM) was renewed
and supplemented by 1% FBS, pen/strep 1% for 72 h, the centrifuga-
tion of plate was performed at 250g/min for 10 min. Then, 100 ll of
each well’s supernatant was added to the wells of a new 96-well
plate, followed by adding 100 ll of LDH test solution to each well
and room temperature incubation for 30 min. Finally, absorbance
was read in 490 nm wavelength and the calculations were done
according to the formula contained in the kit. Each test was
repeated at least three times.2.5. Cell apoptotic rate assay
Induction of NDV induced apoptosis of TC-1 tumor cells was
demonstrated by flow cytometry based Annexin V/PI staining.
The NDV effect on the apoptosis of TC-1 cells was tested via FITC
Annexin-V/PI Apoptosis Detection Kit (BD Biosciences, USA). In
summary, 5  105 cells were seeded in each well of a 6-well plate.
Then, TC-1 cells were infected with NDV at MOIs of 1, 10, 20 and 40
for 1 h and media was renewed by DMEM containing 1% pen/strep
for 72 h. Uninfected cells were considered as control. Further, the
cells were trypsinized and exposed to the medium to neutralize
the effect of trypsin. Next, 5 ml of FITC-conjugated anti-annexin-
V/PI staining antibody (BD Biosciences, USA) and 5 ml of propidium
iodide solution were thoroughly mixed with 100 ml of the binding
buffer. Then, the cells were subjected to 15 min incubation at room
temperature and in darkness, and the cell apoptotic rate was deter-
mined. For flow cytometric Annexin V staining, means of ratio of
annexin V stained cells was compared with their corresponding
controls.2.6. Western blot (WB) analysis
The level of caspase 9 in TC-1 cells was determined via infecting
them with NDV at a MOI of 20. Following 72 h, TC-1 cells were col-
lected and lyzed with RIPA buffer. Following centrifugation, the
supernatant was isolated and filtered through 0.45 lm filter and
protein concentration was calculated by Bicinchoninic acid assay
(BCA) (Thermo Fisher Scientific). The cell lysates were exposed to
15% Sodium Dodecyl Sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Then, proteins were loaded onto the polyvinylidene
difluoride (PVDF) membrane. Followed by membrane blocking
via BSA and overnight exposure to the appropriate primary
anti-caspase 9 and anti-b-actin (loading control) antibodies in a
temperature of 4 C (1:1000, abcam, Cambridge, MA, USA). The
membrane was then washed and exposed to rabbit anti-mouse
secondary antibody (1:10,000, Sigma, St. Louis, MO, USA). Finally,
DAB was used to visualize the obtained bands (Sigma). Densito-
metric assessment of protein bands was done by ImageJ software
(NIH, Bethesda, USA), and their ratio to b-actin was calculated.
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The evaluation of reactive oxygen species (ROS) level was
achieved by 20, 70-dichlorofluorescein diacetate (DCFH-DA). Con-
cisely, the seeding of TC-1 cells was conducted in a 6-well plate
at a density of 5  105 cells per well and then infected with MOI
of 20 for 1 h. Subsequently, media was renewed by DMEM contain-
ing 1% pen/strep for 72 h. After adding DCFH-DA to the samples
(for 1 h), they were trypsinized and washed with PBS. Finally, flu-
orescence intensity of cells was calculated.
2.8. Statistical analysis
All statistical analyses were performed using the Graph Pad
Prism version 5.01 (GraphPad Software, CA, USA). A one-way
ANOVA (followed by Tukey’s post-hoc test) and student’s t-test
were used to compare means among groups. *P < 0.05, **P < 0.01,
and ***P < 0.001 were considered as values of significance.
3. Results
3.1. The Cytotoxicity effect of NDV using MTT assay
To determine whether oncolytic NDV has cytotoxic effects on
TC-1 cells, MTT reduction assay for various MOI of NDV (1–40)
was applied. Because the MTT reduction of mitochondrial enzyme
can only occur in metabolically active cells, the level of activity is
measured as a cell viability. As shown in Fig. 1, NDV effectively
reduced the viability of TC-1 cells, which was MOI-dependent.
The viability in un-infected cells was considered as control. Our
findings also indicated that the viability of the TC-1 cells were
declined to 54% and 43% at a MOI of 20 and 40 respectively
(P < 0.001).
3.2. The cytotoxic effects of NDV using LDH assay
Lactate dehydrogenase (LDH) is a cytosolic enzyme which can
be secreted by necrotic cells. Therefore, intracellular LDH can be
considered as a biomarker for cytolytic activity of NDV. The cyto-
toxic effect of NDV was assessed through LDH release after 72 h
incubation with different MOI on TC-1cells.Fig. 1. Cytotoxicity of NDV on TC-1 cells evaluated by MTT assay. TC-1 cells were
seeded in 96-well plates and treated with various MOIs of NDV for 72 h. The MTT
assay results indicated that infection with 40 MOI can significantly reduce viability
TC-1 cells vs control. ***(P < 0.001) indicates statistically significant difference
between MOIs 40 and 20 compared with control group by one-way ANOVA.
*(P < 0.05) indicates statistically significant difference between MOI 20 compared
with MOI 40 group by one-way ANOVA.As demonstrated in Fig. 2, the rate of LDH release in NDV-
induced TC-1 cells increased in a MOI dependent manner than con-
trol cells. The results also showed that maximum release,
49.8% ± 5.6, was observed 72 h after infection at a MOI of 40 in
the TC-1 cells (P < 0.001). Although TC-1 cultures infected with
40 MOI of NDV did not show statistically significant viability than
cells infected with the 20 MOI (P > 0.05).
3.3. The effect of the NDV on apoptosis induction using annexin V/PI
Assessment of the percentage of apoptosis/necrosis induction in
NDV- treated TC-1 was conducted by using flow cytometry, via
annexin V/PI staining. The means of the percentage ratio of
Annexin V positive and PI negative (early apoptosis/viable cells)
TC-1 cells were plotted for with NDV at different MOIs (Fig. 3).
The results also showed that maximum apoptosis induction
(early stage), 6.3% ± 0.32, was observed 72 h after infection at a
MOI of 40 in the TC-1 cells (P < 0.001). Although TC-1 cultures
infected with 40 MOI of NDV did not show statistically significant
apoptotic activity than cells infected with the 20 MOI (P > 0.05).
The results of experiment indicated that TC-1 cells inoculated with
a MOI of 20 provided the highest oncolytic titer at 72 h post infec-
tion (Zhang et al., 2017). Thus, the MOI of 20 was chosen as opti-
mum dose for subsequent experiments.
3.4. NDV-induced apoptosis in TC-1 cells
In order to assess the expression level of caspase 9 protein in
infected and un-infected cells, the cell lysate supernatants were
exposed to SDS-PAGE and WB after 72 h. As shown in Fig. 4, a sig-
nificant increase in caspase 9 protein was detected in TC-1 cells
infected by NDV with MOI 20 compared to the control group
(p < 0.01).
3.5. The impact of the NDV on intracellular levels of ROS
The induction of ROS has been claimed to be the underlying
modality for various anti-cancer therapies that trigger apoptoticFig. 2. Cytotoxicity of NDV on TC-1 cells evaluated by LDH assay kit. TC-1 cells were
seeded in 96-well plates and treated with various MOIs of NDV for 72 h. The LDH
assay results indicated that infection with 20 MOI can significantly release LDH vs
control. Although TC-1 cultures infected with 40 MOI of NDV did not show
statistically significant viability than cells infected with the 20 MOI (P > 0.05).
**(P < 0.01) indicates statistically significant difference between MOI 20 compared
with MOI 10 group by one-way ANOVA.
Fig. 3. Annexin V/PI staining of TC-1 cells treated with NDV. (A) TC-1 cells were treated with various MOI of NDV (1 to 40) for 72 h, after that expose to Annexin V/PI staining
and analyzed via flow cytometry. Un-treated cells consider as control test. (B) The total percentage of apoptotic cells were stained with annexin V. The results showed
statistically significant difference between all treatment groups (MOIs 1 to 40) compare to control. Results also indicates that no significant difference between MOI 20
compare to MOI 40 group (p > 0.05). ***(P < 0.001) indicates statistically significant difference between all MOIs compared with control group by one-way ANOVA.
Fig. 4. (A) Representative western blotting of Caspase 9 protein after treatment
with NDV (MOI: 20) in TC-1 cells. b-actin was used as a normalizer. (B) The protein
levels of Caspase 9 in TC-1 cells after treatment with NDV (MOI: 20) and their
negative control (un-infected cells). All the experiments were performed in
triplicates. **(P < 0.01) indicates statistically significant difference between MOI 20
compared with control group by Student’s t-test.
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2018). To further confirm apoptotic cell death caused by oncolytic
NDV, we evaluated whether NDV-induced apoptosis in TC-1 cellswas also related with enhanced ROS levels by quantifying intracel-
lular ROS concentrations with DCFH-DA-based flow cytometry. For
this, TC-1 cells were infected with NDV at the MOI of 20 as opti-
mum oncolytic dose. As shown in Fig. 5, an increase in ROS gener-
ation was detected in NDV-induced TC-1 in a MOI -dependent
manner than control cells (p < 0.01).
4. Discussion
The application of oncolytic virus is an attractive therapeutic
strategy for cancer therapy. Oncolytic viruses are described as
genetically engineered or naturally occurring strains that induce
potent adaptive anti-tumor immunity via selectively infecting
cancerous cells without harming the untransformed and normal
tissues (Jhawar et al., 2017, Wei et al., 2018).
So far, a number of oncolytic viruses have demonstrated to be
useful in pre-clinical studies and early clinical trials. Among them,
NDV is known as a tremendously promising oncolytic agent due to
its reasonable safety profile and associated cell death activating
local and distant antitumor immune responses (Choi et al., 2016,
Schirrmacher, 2015).
A number of clinical trials have been directed to use wild type
NDV strains in cancer patients with various types of solid tumors
with no considerable side effects (Sinkovics and Horvath, 2000).
Thus, oncolytic NDV is considered an effective strategy for treating
cancer.
The main objective of this study was to evaluate oncolytic effi-
cacy of LaSota strain on TC-1 tumor cell line, its ability to destroy
these cells in vitro. The murine TC-1 cells of human papillomavirus
(HPV)-related carcinoma which express human papillomavirus 16
(HPV-16) E6/E7 oncoproteins were selected as a model system. For
this purpose, TC-1 cell line was infected with LaSota strain, an
oncolytic NDV, at MOI of 1 to 40 in vitro. To assess and determine
oncolytic titer of NDVwith regard to metabolic activity and cellular
integrity, MTT tests and LDH release assays was performed
respectively.
Fig. 5. DCFH-DA staining of TC-1 cells treated with NDV. (A) TC-1 cells were treated with NDV at MOI 20 for 72 h, Un-treated cells consider as control test. (B) The total
percentage of apoptotic cells were stained with DCFH-DA. The results showed that infection with 20 MOI can significantly release high level of ROS vs control. **(P < 0.01)
indicates statistically significant difference between MOI 20 compared with control group by Student’s t-test.
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amount of purple formazan produced by mitochondrial reduction
of tetrazolium salts. While the leakage of cytoplasmic lactate dehy-
drogenase indicates release of the intracellular contents due to
reduced membrane integrity—apoptotic or necrotic. To investigate
the mechanism of its oncolytic and antitumor activity initially on
HPV cancer cells, flow cytometry was used for detection of apop-
totic cells by annexin V/PI staining and ROSmeasurement. Western
blotting was to evaluate the levels of Caspase 9, an indicator of the
cell apoptosis. Our results showed that NDV LaSota strain induced
effective oncolytic activity against treated TC-1 cell line in a MOI-
dependent manner. The results of MTT and LDH assays demon-
strated significant MOI-dependent cell cytotoxicity of TC-1 cells
with NDV after treatment. The oncolytic virus exerted its antitu-
mor effect through apoptosis as evidenced by annexin V/PI double
staining confirmed the engagement of apoptosis in cell death
induction in MOI-dependent manner compared to control cells.
Measuring the level of Caspase 9 in infected cells in comparison
with the control showed that the NDV activated the internal path-
way of the apoptosis. Moreover, results demonstrated that NDV
LaSota strain leads to ROS accumulation in treated TC-1 tumor in
a MOI- dependent manner in comparison with control cells.
Increasing ROS levels can be resulted in cell death specially in can-
cer cells that contribute to the efficiency of NDV oncolysis.
Consistent with the current results, recent studies have
reported the oncolytic effects of different wild-type NDV strains
on the cell growth of several human cell lines without any side
effect on healthy cells (Yurchenko et al., 2018). Krishnamurthy
et al evaluated oncolytic effect of NDV on human fibrosarcoma
and fibroblast cells. The results indicate that NDV rapidly repli-
cated and destroy human fibrosarcoma cells (HT-1080) but it has
no similar effect on the human skin fibroblast cells as control
(CCD-1122Sk) (Krishnamurthy et al., 2006). In line with previous
researches, another survey determined oncolytic activity of NDV
on the human non-small-cell lung cancer cell line A549. The study
revealed that NDV replication and syncytium formation increased
in A549 tumor cells and leading to apoptosis formation (Mansour
et al., 2011).
The mechanisms of oncolytic NDV-mediated destruction of the
tumor cells have been studied in some recent experiments. The
studies have reported that NDV can suppress growth of broad type
of tumor cells through triggering of apoptosis via mitochondrialintrinsic pathway and the death receptor extrinsic pathway
(Elankumaran et al., 2006, Ravindra et al., 2009).
The apoptosis induced by NDV in HeLa cells has been indicated
to be mediated mostly by activation of TNF-related apoptosis-
inducing ligand (TRAIL) and caspase pathways (Kumar et al.,
2012). In addition, Ravindra et al. also found that mitochondrial
intrinsic apoptotic pathway is a main mechanism of apopto-
sis induction in NDV-infected Vero cell line at 48 h post-infection
(Ravindra et al., 2009). It has been shown that induction of cyto-
pathic effects in NDV-infected cells is initiated by apoptosis that
required viral replication and stimulation of caspase (Ravindra
et al., 2008a). In these experiments, the contribution of the
haemagglutinin neuraminidase (HN) protein in apoptosis triggered
by NDV have been reported (Ravindra et al., 2008b).
ROS are mainly formed in mitochondria and are central contrib-
utors to different types of oxidative stress and cell death (Scherz-
Shouval and Elazar, 2007). The high levels of ROS lead to cell death
enhancing the cellular apoptotic pathway (Gao et al., 2016). ROS
has been linked to autophagic cell death, a cellular process impli-
cated with type II programmed cell death and described by devel-
opment of autophagosomes (Levine and Klionsky, 2004).
Autophagy has been associated in tumor suppression (Jin, 2005).
Consistent with the current results, it has been demonstrated that
secretion of ROS have resulted in apoptosis, mitochondrial impair-
ment, and the caspases stimulation in oncolytic adenovirus–in-
fected gastric adenocarcinoma cell (Wei et al., 2010).
5. Conclusion
In this study, the results reported herein provide evidence of the
cytotoxic potential of a NDV vaccine strain LaSota towards TC-1
cell line of HPV-associated carcinoma, expressing human papillo-
mavirus 16 (HPV-16) E6/E7 oncoproteins. It was demonstrated
that this oncolytic virus induced antitumor activity in the cells
via preferential replication in transformed cells, ROS production
and activation of early apoptosis pathways. The data provide a
novel insight in use of NDV in cervical cancer treatment.
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